Compare LTC Properties Inc (LTC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Sanofi SA — how do they compare? LTC Properties Inc trades at $42.46 (market cap $2.27B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 41.9× LTC Properties Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and Sanofi SA for 94 Days on average.
| LTC | SNY | |
|---|---|---|
Market Cap | $2.27B | $95.18B |
Volume | 574,171 | 2,995,646 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $52.34 |
52-Week Low | $33.98 | $39.51 |
Typical Hold Time | 88 Days | 94 Days |
Enterprise Value | $3.01B | $114.48B |
Dividend Yield | 5.42% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.05, up 0.57% today, with a mixed technical picture showing bearish overall signals but bullish moving averages. The REIT demonstrates strong fundamentals with 38.93% net income margin and consistent dividend payments. Recent acquisitions totaling $160 million in senior housing properties signal aggressive growth strategy, while analyst consensus targets $49.67 with 32% buy ratings.
LTC presents a balanced opportunity with steady income from monthly dividends and strategic SHOP portfolio expansion, though elevated debt levels and rising interest rates pose headwinds. The stock trades below analyst targets but faces execution risks in its transition to 75% SHOP NOI by 2028.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
